Peptron (XKRX:087010) Total Liabilities : ₩17,813 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Peptron Total Liabilities?

Peptron's Total Liabilities for the quarter that ended in Mar. 2024 was ₩17,813 Mil.

Peptron's quarterly Total Liabilities increased from Sep. 2023 (₩15,280.59 Mil) to Dec. 2023 (₩16,368.96 Mil) and increased from Dec. 2023 (₩16,368.96 Mil) to Mar. 2024 (₩17,813.09 Mil).

Peptron's annual Total Liabilities declined from Dec. 2021 (₩15,586.16 Mil) to Dec. 2022 (₩15,165.20 Mil) but then increased from Dec. 2022 (₩15,165.20 Mil) to Dec. 2023 (₩16,368.96 Mil).

Peptron Total Liabilities Historical Data

The historical data trend for Peptron's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Total Liabilities Chart

Peptron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

32,899.83

40,568.21

15,586.16

15,165.20

16,368.96

Peptron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															14,823.25	15,051.73	15,280.59	16,368.96	17,813.09

Peptron Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Peptron's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6884.784	+	(4526.097	+	2079.7
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	2878.381)
	=	16,369

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	52495.975	-	36127.013
	=	16,369

Peptron's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8165.812	+	(4519.571	+	2085.234
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	3042.472)
	=	17,813

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	49909.457	-	32096.367
	=	17,813

Peptron Total Liabilities Related Terms

Thank you for viewing the detailed overview of Peptron's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Peptron (XKRX:087010) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811

Website

http://www.peptron.com

Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines